- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07624968
Protective Effect of Lactation Against Gestational Diabetes Mellitus in Subsequent Pregnancies: A Prospective Observational Cohort Study (LACGDM)
Protective Effect of Lactation Against Gestational Diabetes Mellitus in Subsequent Pregnancy: A Prospective Observational Cohort Study
Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy associated with increased maternal and fetal morbidity. Lactation has been suggested to improve maternal glucose metabolism, enhance insulin sensitivity, and reduce the risk of future glucose intolerance. However, evidence regarding the protective effect of lactation on the development of GDM in subsequent pregnancies remains limited.
This prospective observational cohort study aims to evaluate the association between lactation and the risk of gestational diabetes mellitus and related pregnancy complications in women who conceive during the lactation period. Routine glycemic markers including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results will be recorded. Ultrasonographic findings including fetal abdominal circumference percentile, estimated fetal weight percentile, and amniotic fluid index will also be assessed. The study will investigate whether lactation is associated with a reduced risk of GDM, fetal macrosomia, and polyhydramnios in subsequent pregnancies.
Studienübersicht
Status
Detaillierte Beschreibung
Gestational diabetes mellitus (GDM) is one of the most common metabolic complications of pregnancy and is associated with adverse maternal and neonatal outcomes, including fetal macrosomia, polyhydramnios, cesarean delivery, and future development of type 2 diabetes mellitus. Early identification of women at increased risk of GDM is essential for optimizing antenatal care and improving pregnancy outcomes.
Lactation has been reported to exert beneficial metabolic effects through increased glucose utilization, improved insulin sensitivity, and facilitation of postpartum weight loss. Previous studies have suggested that breastfeeding may reduce the long-term risk of type 2 diabetes in women with a history of GDM. However, evidence regarding the protective effect of lactation on the occurrence of gestational diabetes mellitus in subsequent pregnancies remains limited.
The present prospective observational cohort study aims to evaluate the relationship between lactation and the development of gestational diabetes mellitus in women who become pregnant during the lactation period. Pregnant women aged 18-50 years with singleton pregnancies who attend the participating obstetrics and gynecology clinics will be enrolled. Routine laboratory parameters obtained during antenatal care, including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results, will be recorded.
In addition, routine ultrasonographic measurements, including fetal abdominal circumference percentile (AC), estimated fetal weight percentile (EFW), and amniotic fluid index (AFI), will be collected during the second and third trimesters. Maternal demographic and obstetric characteristics, including age, gravidity, parity, abortion history, and educational status, will also be documented.
The primary objective of the study is to determine whether lactation is associated with a reduced risk of gestational diabetes mellitus. Secondary objectives include evaluating the association between lactation and pregnancy complications related to altered glucose metabolism, including fetal macrosomia and polyhydramnios. The findings of this study may contribute to a better understanding of the metabolic effects of lactation and provide evidence for strategies aimed at reducing the burden of gestational diabetes mellitus in future pregnancy.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Burak D AYDOGDU, MD, OB/GYN
- Telefonnummer: +90 5396182228
- E-Mail: burakd.1992@hotmail.com
Studienorte
-
-
-
Istanbul, Türkei (türkiye), 34384
- Rekrutierung
- Prof. Dr. Cemil Taşcıoğlu City Hospital
-
Kontakt:
- Burak d AYDOGDU, MD
- Telefonnummer: 90 5396182228
- E-Mail: burakd.1992@hotmail.com
-
Istanbul, Türkei (türkiye), 34517
- Rekrutierung
- Esenyurt Necmi Kadıoğlu State Hospital
-
Kontakt:
- Burak d AYDOGDU, MD
- Telefonnummer: +90 5396182228
- E-Mail: burakd.1992@hotmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Pregnant individuals aged 18 to 50 years.
- Singleton pregnancy.
- Conception during the lactation period.
- Follow-up at Prof. Dr. Cemil Taşcıoğlu City Hospital or Esenyurt Necmi Kadıoğlu State Hospital.
- Availability of glycemic parameters including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results.
- Availability of routine ultrasonographic measurements including fetal abdominal circumference percentile (AC), estimated fetal weight percentile (EFW), and amniotic fluid index (AFI).
Exclusion Criteria:
- Age below 18 years.
- Age above 50 years.
- Multiple pregnancy.
- Known chronic systemic disease or pre-existing diabetes mellitus.
- Missing clinical, laboratory, or ultrasonographic data.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Pregnant Women During Lactation Period
Singleton pregnant women aged 18-50 years who conceived during the lactation period and were followed at participating obstetrics and gynecology clinics.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Gestational Diabetes Mellitus
Zeitfenster: 24-28 weeks of gestation
|
Occurrence of gestational diabetes mellitus diagnosed by the 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation.
|
24-28 weeks of gestation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fetal Macrosomia
Zeitfenster: From second trimester until delivery
|
Presence of fetal macrosomia assessed according to routine obstetric ultrasonographic evaluation and/or birth weight.
|
From second trimester until delivery
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Polyhydramnios
Zeitfenster: From second trimester until delivery
|
Development of polyhydramnios determined by routine ultrasonographic assessment of amniotic fluid volume during pregnancy.
|
From second trimester until delivery
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Stoffwechselerkrankungen
- Schwangerschaftskomplikationen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Ernährungs- und Stoffwechselerkrankungen
- Schwangerschaftsdiabetes
Andere Studien-ID-Nummern
- LAC-GDM-2026-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schwangerschaftsdiabetes mellitus (GDM)
-
Chinese University of Hong KongAnmeldung auf EinladungGDM | Schwangerschaftsdiabetes mellitusHongkong
-
Chinese University of Hong KongAnmeldung auf EinladungGDM | Schwangerschaftsdiabetes mellitus (GDM)Hongkong
-
Sansum Diabetes Research InstituteAbgeschlossenDiabetes mellitus, Typ 2 | Diabetes Mel Gestational – in der SchwangerschaftVereinigte Staaten
-
University of Turin, ItalyAbgeschlossenSchwangerschaftsdiabetes mellitus (GDM)Italien
-
Peking Union Medical College HospitalBeijing Chao Yang Hospital; Beijing Obstetrics and Gynecology Hospital; San MediTech(Huzhou)Co... und andere MitarbeiterUnbekanntSANZ®KINGWILL in Kombination mit CGM-Geräten bei GDM-Patienten | GLUCERNA SR® in Kombination mit CGM-Geräten bei GDM-PatientenChina
-
Institute of Mother and Child, Warsaw, PolandNoch keine RekrutierungNeugeborene Hypoglykämie | Schwangerschaftsdiabetes mellitus (GDM)Polen
-
Hospital Clinic of BarcelonaFundación Sociedad Española de DiabetesNoch keine RekrutierungSchwangerschaftsdiabetes mellitus (GDM)Spanien
-
Saglik Bilimleri UniversitesiAktiv, nicht rekrutierendSchwangerschaftsdiabetes mellitus (GDM)Türkei (türkiye)
-
Peking UniversityNational Natural Science Foundation of ChinaNoch keine RekrutierungSchwangerschaftsdiabetes mellitus (GDM)China
-
University of UlmRekrutierungSchwangerschaftsdiabetes mellitus (GDM)Deutschland